The Expanding Role Of GLP-1 Receptor Agonists In CNS Clinical Research

By Djouher Hough, Psy.D., Executive Director of Clinical Sciences, CRC

Medications originally designed to manage blood sugar and weight in type 2 diabetes are now being explored for treating brain-related conditions, particularly substance use disorders and neurological diseases. Recent observations suggest that one class of these drugs—GLP-1 receptor agonists—may reduce cravings and consumption of alcohol and tobacco, with emerging evidence that they could help address opioid use disorder, cocaine dependence, and neurodegenerative diseases like Alzheimer's and Parkinson's.

Clinical trials are currently underway to rigorously evaluate whether these medications can reduce addictive behaviors and their recurrence, using both quantitative measures. Learn more about how, if validated, this repurposing could provide much-needed treatment options for millions struggling with addiction and neurodegenerative conditions.